Original from: Genomeweb
The US Food and Drug Administration on Tuesday granted Emergency Use Authorization for a molecular COVID-19/flu test from Lucira Health.
The Lucira COVID-19 & Flu test was authorized for use at the point of care. According to the agency, it is the first molecular COVID-19 test to receive authorization following collaboration with the US National Institutes of Health's Independent Test Assessment Program (ITAP), which was created to speed up the regulatory review of over-the-counter COVID-19 tests.
The RT-LAMP-based test, developed by Emeryville, California-based Lucira, is for single use. It detects and differentiates between SARS-CoV-2, influenza A, and influenza B viral RNA in anterior nasal swab samples collected by a healthcare provider from individuals suspected of having COVID-19. The test is for use by CLIA-certified laboratories only.
Source: Lucira Health Molecular COVID/Flu Test Gets FDA Emergency Use Authorization
Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.